List of works - Supachai Rerks-Ngarm

A novel mechanism linking memory stem cells with innate immunity in protection against HIV-1 infection

scientific article

A novel strategy to adapt SHIV-E1 carrying env from an RV144 volunteer to rhesus macaques: coreceptor switch and final recovery of a pathogenic virus with exclusive R5 tropism

scientific article

A reply to the Letter to the Editor by Mäkelä, Herva and Nohynek in response to the article by Rerks-Ngarm S, Treleaven SC, Chunsuttiwat S, Muangchana C, Jolley D, Brooks A, Dejsirilert S, Warintrawat S, Guiver M, Kunasol P, Maynard JE, Biggs B-A, S

scientific article

AIDS vaccine for Asia Network (AVAN): expanding the regional role in developing HIV vaccines

scientific article

Accelerating the development of an AIDS vaccine: the AIDS vaccine for Asia Network (Avan)

scientific article published on September 1, 2011

Accuracy of Clinical Diagnosis of Dengue Episodes in the RV144 HIV Vaccine Efficacy Trial in Thailand

scientific article

Aggregate complexes of HIV-1 induced by multimeric antibodies

scientific article

An HIV Vaccine for South-East Asia-Opportunities and Challenges

scientific article published on 14 August 2013

Analysis of HLA A*02 association with vaccine efficacy in the RV144 HIV-1 vaccine trial

scientific article

Analysis of V2 antibody responses induced in vaccinees in the ALVAC/AIDSVAX HIV-1 vaccine efficacy trial

scientific article

Antibody light-chain-restricted recognition of the site of immune pressure in the RV144 HIV-1 vaccine trial is phylogenetically conserved

scientific article

Antibody to HSV gD peptide induced by vaccination does not protect against HSV-2 infection in HSV-2 seronegative women

scientific article

Antibody-dependent cellular cytotoxicity-mediating antibodies from an HIV-1 vaccine efficacy trial target multiple epitopes and preferentially use the VH1 gene family

scientific article

Antigenicity and immunogenicity of RV144 vaccine AIDSVAX clade E envelope immunogen is enhanced by a gp120 N-terminal deletion

scientific article published on 21 November 2012

Bacterial meningitis incidence in Thai children estimated by a rapid assessment tool (RAT).

scientific article published in May 2009

Boosting of HIV envelope CD4 binding site antibodies with long variable heavy third complementarity determining region in the randomized double blind RV305 HIV-1 vaccine trial.

scientific article

Boosting with AIDSVAX B/E Enhances Env Constant Region 1 and 2 Antibody-Dependent Cellular Cytotoxicity Breadth and Potency

scientific article published on 31 January 2020

CD8 and CD4 epitope predictions in RV144: no strong evidence of a T-cell driven sieve effect in HIV-1 breakthrough sequences from trial participants.

scientific article

COMPASS identifies T-cell subsets correlated with clinical outcomes

scientific article

Characterization of HIV-1 gp120 antibody specificities induced in anogenital secretions of RV144 vaccine recipients after late boost immunizations

scientific article published on 27 April 2018

Comparison of Antibody Responses Induced by RV144, VAX003, and VAX004 Vaccination Regimens

scientific article

Comprehensive sieve analysis of breakthrough HIV-1 sequences in the RV144 vaccine efficacy trial

scientific article

Defining the objectives of the AIDS vaccine for Asia network: report of the WHO-UNAIDS/Global HIV vaccine enterprise regional consultation on expanding AIDS vaccine research and development capacity in Asia ⬇️

scientific article

Distinct susceptibility of HIV vaccine vector-induced CD4 T cells to HIV infection.

scientific article published on 23 February 2018

Expanding research capacity and accelerating AIDS vaccine development in Asia

scientific article

Expectation of volunteers towards the vaccine efficacy of the prime-boost HIV vaccine phase III trial during unblinding

scientific article

Extended Evaluation of the Virologic, Immunologic, and Clinical Course of Volunteers Who Acquired HIV-1 Infection in a Phase III Vaccine Trial of ALVAC-HIV and AIDSVAX B/E ⬇️

scientific article published on July 26, 2012

FCGR2C polymorphisms associate with HIV-1 vaccine protection in RV144 trial

scientific article

HIV vaccine delayed boosting increases Env variable region 2-specific antibody effector functions

scientific article published on 30 January 2020

HIV vaccines: lessons learned and the way forward ⬇️

scientific article published on September 1, 2010

HIV-1 Envelope Glycoproteins from Diverse Clades Differentiate Antibody Responses and Durability among Vaccinees

scientific article published on 31 January 2018

HIV-1 infections with multiple founders are associated with higher viral loads than infections with single founders

scientific article

HIV-1 specific IgA Monoclonal Antibodies from an HIV-1 Vaccinee Mediate Galcer Blocking and Phagocytosis

scientific article published on 10 January 2018

HIV-1 vaccine-induced C1 and V2 Env-specific antibodies synergize for increased antiviral activities

scientific article

HIV-specific antibody-dependent phagocytosis matures during HIV infection.

scientific article published on 10 June 2014

HIV/AIDS preventive vaccine 'prime-boost' phase III trial: foundations and initial lessons learned from Thailand

scientific article published on 01 July 2006

HLA class I, KIR, and genome-wide SNP diversity in the RV144 Thai phase 3 HIV vaccine clinical trial

scientific article

HLA class II genes modulate vaccine-induced antibody responses to affect HIV-1 acquisition

scientific article published on July 2015

Human Non-neutralizing HIV-1 Envelope Monoclonal Antibodies Limit the Number of Founder Viruses during SHIV Mucosal Infection in Rhesus Macaques

scientific article

Identification of New Regions in HIV-1 gp120 Variable 2 and 3 Loops that Bind to α4β7 Integrin Receptor

scientific article published in December 2015

Identification of immunodominant CD4-restricted epitopes co-located with antibody binding sites in individuals vaccinated with ALVAC-HIV and AIDSVAX B/E.

scientific article

Immune-correlates analysis of an HIV-1 vaccine efficacy trial

scientific article (publication date: 5 April 2012)

Increased HIV-1 vaccine efficacy against viruses with genetic signatures in Env V2

scientific article

Infant HIV type 1 gp120 vaccination elicits robust and durable anti-V1V2 immunoglobulin G responses and only rare envelope-specific immunoglobulin A responses

scientific article

Infectious virion capture by HIV-1 gp120-specific IgG from RV144 vaccinees

scientific article published on 08 May 2013

Issues in women's participation in a phase III community HIV vaccine trial in Thailand

scientific article published on 25 February 2013

Letter to the Editor on: The RV144 vaccine regimen was not associated with enhancement of infection

scientific article published on January 2015

Machine learning methods enable predictive modeling of antibody feature:function relationships in RV144 vaccinees

scientific article

Magnitude and breadth of the neutralizing antibody response in the RV144 and Vax003 HIV-1 vaccine efficacy trials

scientific article

Modulation of Vaccine-Induced CD4 T Cell Functional Profiles by Changes in Components of HIV Vaccine Regimens in Humans

article

Molecular evolution of the HIV-1 Thai epidemic between the time of RV144 immunogen selection to the execution of the vaccine efficacy trial

scientific article published on 10 April 2013

Monoclonal Antibodies, Derived from Humans Vaccinated with the RV144 HIV Vaccine Containing the HVEM Binding Domain of Herpes Simplex Virus (HSV) Glycoprotein D, Neutralize HSV Infection, Mediate Antibody-Dependent Cellular Cytotoxicity, and Protect

scientific article published on 12 July 2017

Neutralization Takes Precedence Over IgG or IgA Isotype-related Functions in Mucosal HIV-1 Antibody-mediated Protection

scientific article

Optimization and qualification of a multiplex bead array to assess cytokine and chemokine production by vaccine-specific cells

scientific article

Plasma IgG to linear epitopes in the V2 and V3 regions of HIV-1 gp120 correlate with a reduced risk of infection in the RV144 vaccine efficacy trial

scientific article

Polyfunctional Fc-effector profiles mediated by IgG subclass selection distinguish RV144 and VAX003 vaccines

scientific article published on March 2014

Preparing for the availability of a partially effective HIV vaccine: Some lessons from other licensed vaccines ⬇️

scientific article published on July 13, 2011

Prospective population-based incidence of Haemophilus influenzae type b meningitis in Thailand

scholarly article by Supachai Rerks-Ngarm et al published February 2004 in Vaccine

Randomized, Double-Blind Evaluation of Late Boost Strategies for HIV-Uninfected Vaccine Recipients in the RV144 HIV Vaccine Efficacy Trial

scientific article

Risk behaviour and time as covariates for efficacy of the HIV vaccine regimen ALVAC-HIV (vCP1521) and AIDSVAX B/E: a post-hoc analysis of the Thai phase 3 efficacy trial RV 144.

scientific article

Safety and reactogenicity of canarypox ALVAC-HIV (vCP1521) and HIV-1 gp120 AIDSVAX B/E vaccination in an efficacy trial in Thailand

scientific article published in 2011

Structural analysis of the unmutated ancestor of the HIV-1 envelope V2 region antibody CH58 isolated from an RV144 vaccine efficacy trial vaccinee

scientific article published on 20 June 2015

The Thai Phase III HIV Type 1 Vaccine trial (RV144) regimen induces antibodies that target conserved regions within the V2 loop of gp120.

scientific article

The Thai Phase III Trial (RV144) Vaccine Regimen Induces T Cell Responses That Preferentially Target Epitopes within the V2 Region of HIV-1 Envelope ⬇️

scientific article published on April 23, 2012

Tissue memory B cell repertoire analysis after ALVAC/AIDSVAX B/E gp120 immunization of rhesus macaques

scientific article published on 08 December 2016

V1V2-specific complement activating serum IgG as a correlate of reduced HIV-1 infection risk in RV144.

scientific article

Vaccine Induction of Antibodies against a Structurally Heterogeneous Site of Immune Pressure within HIV-1 Envelope Protein Variable Regions 1 and 2

scientific article

Vaccine-induced Env V1-V2 IgG3 correlates with lower HIV-1 infection risk and declines soon after vaccination

scientific article

Vaccine-induced HIV-1 envelope gp120 constant region 1-specific antibodies expose a CD4-inducible epitope and block the interaction of HIV-1 gp140 with galactosylceramide

scientific article

Vaccine-induced Human Antibodies Specific for the Third Variable Region of HIV-1 gp120 Impose Immune Pressure on Infecting Viruses

scientific article

Vaccine-induced IgG antibodies to V1V2 regions of multiple HIV-1 subtypes correlate with decreased risk of HIV-1 infection

scientific article

Vaccine-induced plasma IgA specific for the C1 region of the HIV-1 envelope blocks binding and effector function of IgG.

scientific article published on 9 May 2013

List of works by Supachai Rerks-Ngarm

A novel mechanism linking memory stem cells with innate immunity in protection against HIV-1 infection

A novel strategy to adapt SHIV-E1 carrying env from an RV144 volunteer to rhesus macaques: coreceptor switch and final recovery of a pathogenic virus with exclusive R5 tropism

A reply to the Letter to the Editor by Mäkelä, Herva and Nohynek in response to the article by Rerks-Ngarm S, Treleaven SC, Chunsuttiwat S, Muangchana C, Jolley D, Brooks A, Dejsirilert S, Warintrawat S, Guiver M, Kunasol P, Maynard JE, Biggs B-A, S

AIDS vaccine for Asia Network (AVAN): expanding the regional role in developing HIV vaccines

Accelerating the development of an AIDS vaccine: the AIDS vaccine for Asia Network (Avan)

Accuracy of Clinical Diagnosis of Dengue Episodes in the RV144 HIV Vaccine Efficacy Trial in Thailand

Aggregate complexes of HIV-1 induced by multimeric antibodies

An HIV Vaccine for South-East Asia-Opportunities and Challenges

Analysis of HLA A*02 association with vaccine efficacy in the RV144 HIV-1 vaccine trial

Analysis of V2 antibody responses induced in vaccinees in the ALVAC/AIDSVAX HIV-1 vaccine efficacy trial

Antibody light-chain-restricted recognition of the site of immune pressure in the RV144 HIV-1 vaccine trial is phylogenetically conserved

Antibody to HSV gD peptide induced by vaccination does not protect against HSV-2 infection in HSV-2 seronegative women

Antibody-dependent cellular cytotoxicity-mediating antibodies from an HIV-1 vaccine efficacy trial target multiple epitopes and preferentially use the VH1 gene family

Antigenicity and immunogenicity of RV144 vaccine AIDSVAX clade E envelope immunogen is enhanced by a gp120 N-terminal deletion

Bacterial meningitis incidence in Thai children estimated by a rapid assessment tool (RAT).

Boosting of HIV envelope CD4 binding site antibodies with long variable heavy third complementarity determining region in the randomized double blind RV305 HIV-1 vaccine trial.

Boosting with AIDSVAX B/E Enhances Env Constant Region 1 and 2 Antibody-Dependent Cellular Cytotoxicity Breadth and Potency

CD8 and CD4 epitope predictions in RV144: no strong evidence of a T-cell driven sieve effect in HIV-1 breakthrough sequences from trial participants.

COMPASS identifies T-cell subsets correlated with clinical outcomes

Characterization of HIV-1 gp120 antibody specificities induced in anogenital secretions of RV144 vaccine recipients after late boost immunizations

Comparison of Antibody Responses Induced by RV144, VAX003, and VAX004 Vaccination Regimens

Comprehensive sieve analysis of breakthrough HIV-1 sequences in the RV144 vaccine efficacy trial

Defining the objectives of the AIDS vaccine for Asia network: report of the WHO-UNAIDS/Global HIV vaccine enterprise regional consultation on expanding AIDS vaccine research and development capacity in Asia ⬇️

Distinct susceptibility of HIV vaccine vector-induced CD4 T cells to HIV infection.

Expanding research capacity and accelerating AIDS vaccine development in Asia

Expectation of volunteers towards the vaccine efficacy of the prime-boost HIV vaccine phase III trial during unblinding

Extended Evaluation of the Virologic, Immunologic, and Clinical Course of Volunteers Who Acquired HIV-1 Infection in a Phase III Vaccine Trial of ALVAC-HIV and AIDSVAX B/E ⬇️

FCGR2C polymorphisms associate with HIV-1 vaccine protection in RV144 trial

HIV vaccine delayed boosting increases Env variable region 2-specific antibody effector functions

HIV vaccines: lessons learned and the way forward ⬇️

HIV-1 Envelope Glycoproteins from Diverse Clades Differentiate Antibody Responses and Durability among Vaccinees

HIV-1 infections with multiple founders are associated with higher viral loads than infections with single founders

HIV-1 specific IgA Monoclonal Antibodies from an HIV-1 Vaccinee Mediate Galcer Blocking and Phagocytosis

HIV-1 vaccine-induced C1 and V2 Env-specific antibodies synergize for increased antiviral activities

HIV-specific antibody-dependent phagocytosis matures during HIV infection.

HIV/AIDS preventive vaccine 'prime-boost' phase III trial: foundations and initial lessons learned from Thailand

HLA class I, KIR, and genome-wide SNP diversity in the RV144 Thai phase 3 HIV vaccine clinical trial

HLA class II genes modulate vaccine-induced antibody responses to affect HIV-1 acquisition

Human Non-neutralizing HIV-1 Envelope Monoclonal Antibodies Limit the Number of Founder Viruses during SHIV Mucosal Infection in Rhesus Macaques

Identification of New Regions in HIV-1 gp120 Variable 2 and 3 Loops that Bind to α4β7 Integrin Receptor

Identification of immunodominant CD4-restricted epitopes co-located with antibody binding sites in individuals vaccinated with ALVAC-HIV and AIDSVAX B/E.

Immune-correlates analysis of an HIV-1 vaccine efficacy trial

Increased HIV-1 vaccine efficacy against viruses with genetic signatures in Env V2

Infant HIV type 1 gp120 vaccination elicits robust and durable anti-V1V2 immunoglobulin G responses and only rare envelope-specific immunoglobulin A responses

Infectious virion capture by HIV-1 gp120-specific IgG from RV144 vaccinees

Issues in women's participation in a phase III community HIV vaccine trial in Thailand

Letter to the Editor on: The RV144 vaccine regimen was not associated with enhancement of infection

Machine learning methods enable predictive modeling of antibody feature:function relationships in RV144 vaccinees

Magnitude and breadth of the neutralizing antibody response in the RV144 and Vax003 HIV-1 vaccine efficacy trials

Modulation of Vaccine-Induced CD4 T Cell Functional Profiles by Changes in Components of HIV Vaccine Regimens in Humans

Molecular evolution of the HIV-1 Thai epidemic between the time of RV144 immunogen selection to the execution of the vaccine efficacy trial

Monoclonal Antibodies, Derived from Humans Vaccinated with the RV144 HIV Vaccine Containing the HVEM Binding Domain of Herpes Simplex Virus (HSV) Glycoprotein D, Neutralize HSV Infection, Mediate Antibody-Dependent Cellular Cytotoxicity, and Protect

Neutralization Takes Precedence Over IgG or IgA Isotype-related Functions in Mucosal HIV-1 Antibody-mediated Protection

Optimization and qualification of a multiplex bead array to assess cytokine and chemokine production by vaccine-specific cells

Plasma IgG to linear epitopes in the V2 and V3 regions of HIV-1 gp120 correlate with a reduced risk of infection in the RV144 vaccine efficacy trial

Polyfunctional Fc-effector profiles mediated by IgG subclass selection distinguish RV144 and VAX003 vaccines

Preparing for the availability of a partially effective HIV vaccine: Some lessons from other licensed vaccines ⬇️

Prospective population-based incidence of Haemophilus influenzae type b meningitis in Thailand

Randomized, Double-Blind Evaluation of Late Boost Strategies for HIV-Uninfected Vaccine Recipients in the RV144 HIV Vaccine Efficacy Trial

Risk behaviour and time as covariates for efficacy of the HIV vaccine regimen ALVAC-HIV (vCP1521) and AIDSVAX B/E: a post-hoc analysis of the Thai phase 3 efficacy trial RV 144.

Safety and reactogenicity of canarypox ALVAC-HIV (vCP1521) and HIV-1 gp120 AIDSVAX B/E vaccination in an efficacy trial in Thailand

Structural analysis of the unmutated ancestor of the HIV-1 envelope V2 region antibody CH58 isolated from an RV144 vaccine efficacy trial vaccinee

The Thai Phase III HIV Type 1 Vaccine trial (RV144) regimen induces antibodies that target conserved regions within the V2 loop of gp120.

The Thai Phase III Trial (RV144) Vaccine Regimen Induces T Cell Responses That Preferentially Target Epitopes within the V2 Region of HIV-1 Envelope ⬇️

Tissue memory B cell repertoire analysis after ALVAC/AIDSVAX B/E gp120 immunization of rhesus macaques

V1V2-specific complement activating serum IgG as a correlate of reduced HIV-1 infection risk in RV144.

Vaccine Induction of Antibodies against a Structurally Heterogeneous Site of Immune Pressure within HIV-1 Envelope Protein Variable Regions 1 and 2

Vaccine-induced Env V1-V2 IgG3 correlates with lower HIV-1 infection risk and declines soon after vaccination

Vaccine-induced HIV-1 envelope gp120 constant region 1-specific antibodies expose a CD4-inducible epitope and block the interaction of HIV-1 gp140 with galactosylceramide

Vaccine-induced Human Antibodies Specific for the Third Variable Region of HIV-1 gp120 Impose Immune Pressure on Infecting Viruses

Vaccine-induced IgG antibodies to V1V2 regions of multiple HIV-1 subtypes correlate with decreased risk of HIV-1 infection

Vaccine-induced plasma IgA specific for the C1 region of the HIV-1 envelope blocks binding and effector function of IgG.